Group 1: Macroeconomic News - The price of 92-octane gasoline may return to the 6 yuan era, marking a four-year low, with a projected decrease of 320 yuan/ton, translating to a drop of 0.24 to 0.27 yuan per liter [2] - The current average price of 92-octane gasoline is 7.04 yuan/liter, expected to fall to a range of 6.77 to 6.80 yuan/liter after the adjustment [2] Group 2: Satellite and Space Technology - The first "Xiong'an-made" satellite, "Xiong'an No. 1," has completed production, marking a significant milestone in the intelligent manufacturing capabilities of the aerospace industry in Xiong'an New Area [2] - The satellite focuses on three key technological innovations: high-performance onboard computers, large flexible solar wings, and a new generation of Hall electric propulsion systems [2] Group 3: Pharmaceutical Industry - The first AI-assisted new drug MTS-004 has successfully completed Phase III clinical trials, becoming the first of its kind in China [3] - MTS-004 is designed for treating Pseudobulbar Affect (PBA) and addresses common swallowing difficulties with an orally disintegrating tablet formulation [3] Group 4: Technology and Innovation - Guangzhou has introduced a systematic action plan to accelerate the development of future industries, focusing on a dynamic development system that includes six core industries and multiple potential tracks [5] - The plan emphasizes continuous monitoring, technology sourcing, scenario-driven development, and collaborative governance to foster innovation [5] Group 5: Market Movements - The Hang Seng Technology Index fell by 2.12%, with major tech stocks experiencing declines, including NetEase down over 5% and Baidu and Alibaba down nearly 3% [5] - International spot gold prices saw a significant drop, with a one-day decline exceeding 6%, marking the largest drop in 12 years [5][6] Group 6: Corporate Developments - Cambrian Technology saw a surge of over 7%, with its market capitalization returning above 600 billion yuan, driven by positive sentiment in the computing chip sector [7] - Huawei announced the release of HarmonyOS 6, with over 23 million terminal devices now using HarmonyOS, highlighting significant user engagement and ecosystem development [8] - Yushun Technology received a patent for a robot joint control method based on motion capture technology, enhancing human-robot interaction capabilities [8] Group 7: Apple Inc. Developments - Apple's large foldable iPad project faces engineering challenges, potentially delaying its launch to 2029 or later due to issues with weight, functionality, and display technology [9]

Group 1: Industry Performance Overview - The performance forecast for Q3 2025 shows bright prospects in the electronics and basic chemicals sectors, with over 10 companies expected to achieve a profit growth rate exceeding 30% year-on-year [1] - The electronics sector is benefiting from the AI wave, which is driving new demand and maintaining high growth [1] - The basic chemicals industry is experiencing structural improvement due to supply constraints and demand support, with some sectors already showing signs of recovery [1] Group 2: Market Trends and Signals - The market has shifted from an upward trend to a volatile pattern, influenced by ongoing US-China trade conflicts, which negatively affect market risk appetite [2] - Technical indicators suggest a potential market rebound, with a recommendation to reduce positions to a neutral level while waiting for volume signals [2] - The industry allocation model indicates that dividend assets and sectors benefiting from policy support, such as photovoltaics and chemicals, remain worthy of attention [2] Group 3: Medical Equipment Sector Insights - The medical equipment sector reported a decline in revenue and net profit for H1 2025, with revenues down 7.3% and net profits down 27% year-on-year [6] - There is a significant recovery in bidding activities, with a 64% year-on-year increase in the total amount of domestic medical equipment bids in H1 2025 [6] - Companies like Yingli Medical and Mindray are seeing growth in overseas revenues, indicating a trend towards globalization [7] Group 4: Debt Market Analysis - The debt market is currently influenced by risk aversion, with a mixed performance observed due to trade tensions and equity market behavior [4] - The focus is on interest rate spreads and the potential for short-term trading opportunities, particularly around the upcoming 20th Central Committee meeting [4] Group 5: Future Growth Projections - The company is expected to achieve significant revenue growth in the coming years, with projected revenues of 46.45 billion, 56.84 billion, and 71.74 billion yuan from 2025 to 2027 [12] - The lithium battery equipment sector is anticipated to see a compound annual growth rate (CAGR) of 34% in overseas revenue from 2020 to 2024, indicating strong international demand [14] - The new drug development sector is expected to grow steadily, with projected revenues of 5.04 billion, 6.08 billion, and 7.39 billion yuan from 2025 to 2027 [17]

Group 1 - The report highlights that the performance forecasts for Q3 2025 in the electronics and basic chemicals sectors are promising, with over 10 companies expected to achieve a profit growth rate exceeding 30% year-on-year [3][29] - In the electronics sector, the AI wave is driving high growth, with AI inference creating new demand, suggesting that the sector is likely to maintain a high prosperity level [3][29] - The basic chemicals sector is experiencing structural improvement due to supply constraints and demand support, with an overall balance of supply and demand expected to improve as capacity adjustments take place [3][29] Group 2 - The report indicates that as of October 15, 2025, 154 companies in the A-share market have disclosed their Q3 2025 performance forecasts or reports, with a disclosure rate of approximately 2.83% and a pre-positive forecast rate of about 83.06% [3][30] - The median net profit growth rate for the sample companies disclosing their performance forecasts is 71.2% under the median method and 65.6% under the overall method [3][30] - The report identifies that the sectors with the highest pre-positive forecast rates include comprehensive, non-bank financial, and social services, all at 100% [3][30] Group 3 - The medical device sector saw a decline in revenue and net profit in H1 2025, with overall revenue down 7.3% and net profit down 27.0% year-on-year [8] - However, the bidding process is recovering, with the total amount of domestic medical device bids in H1 2025 reaching 83.8 billion yuan, a year-on-year increase of 64% [8] - Companies like United Imaging and Mindray are experiencing growth in overseas revenues, indicating a trend towards globalization in the medical device market [8] Group 4 - The report emphasizes the importance of AI hardware and domestic computing power as key investment areas, suggesting that the market may continue to see structural slow growth with technology remaining a core focus [10] - The electronics sector is expected to see significant advancements in AI terminal ecosystems, with hardware innovation and computing power working in synergy, potentially leading to a boom in 2026 [12] - The report also notes that major companies like Apple are enhancing their collaboration in the AI space, which could lead to a reevaluation of industry valuations [12]

香 港 交 易 及 結 算 所 有 限 公 司、香 港 聯 合 交 易 所 有 限 公 司（「聯交所」）及香港中央 結算有限公司（「香港結算」）對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 除 本 公 告 另 有 界 定 者 外，本 公 告 所 用 詞 彙 與 福 建 海 西 新 藥 創 制 股 份 有 限 公 司 （「本公司」）刊發日期為2025年10月9日的招股章程（「招股章程」）所界定者具有相 同 涵 義。 本 公 告 僅 作 參 考 用 途，並 不 構 成 收 購、購 買 或 認 購 本 公 司 證 券 的 邀 請 或 要 約。 本 公 告 並 非 招 股 章 程。潛 在 投 資 者 於 決 定 是 否 投 資 於 發 售 股 份 前 應 閱 覽 招 股 章 程，以 獲 得 有 關 全 球 發 售 的 詳 細 資 料。 本公告不會直接或間接於或向美國（包 ...

Core Insights - The 56th National Medicinal Materials and Pharmaceuticals Trade Fair opened in Zhangshu City, Jiangxi, featuring over 1,000 pharmaceutical companies, including more than 40 of China's top pharmaceutical enterprises [1] - The theme of the conference is "Inheriting Essence, Improving Quality, and Innovating," showcasing nearly 1,000 products across the entire industry chain, including traditional Chinese medicine, proprietary Chinese medicines, pharmaceutical equipment, and health products [1] - The event includes 12 specialized exhibition areas, with a new section dedicated to the transfer of innovative drug approvals, aimed at connecting approval holders with production companies [1] Industry Developments - A promotional meeting for investment attraction in Jiangxi's pharmaceutical industry was held, resulting in the signing of 10 projects across various sectors, including medical devices, pharmaceutical chemicals, traditional Chinese medicine cultivation, and new drug research and development [1] - Zhangshu City is implementing the "China Medicine Capital" revitalization project, transitioning the traditional Chinese medicine industry from "traditional processing" to "modern manufacturing" and enhancing the value of medicinal materials [1] - The city currently has over 500 pharmaceutical companies, including 50 national high-tech enterprises in the pharmaceutical sector, and has been recognized as a four-star national new industrialization industry demonstration base [1]

Core Viewpoint - HaiXi Pharmaceutical (02637) is set to list on the Hong Kong Stock Exchange on October 17, with pre-listing trading indicating a significant price increase from the initial offering price [1]. Group 1: Listing Details - HaiXi Pharmaceutical will officially list on October 17, 2023 [1]. - The initial offering price was set at HKD 86.4, while the dark trading price is currently at HKD 130.9, reflecting a 51.5% increase [1][2]. Group 2: Trading Performance - The dark trading volume reached 61,100 shares, with a highest price of HKD 176.0 and a lowest price of HKD 129.0 [2]. - The total market capitalization of HaiXi Pharmaceutical is approximately HKD 10.303 billion [2]. - The average trading price during the session was HKD 136.275, with a turnover rate of 0.08% [2].

Core Viewpoint - The largest shareholder of Amgen Pharmaceuticals, Genie Pharma, has initiated a strong counteraction by proposing the removal of the chairman and three directors, while also publicly soliciting voting rights to oppose several resolutions at the upcoming shareholder meeting [2][6]. Group 1: Shareholder Actions - Genie Pharma voted against multiple resolutions at the extraordinary general meeting scheduled for 2025, including a proposed capital increase [2]. - Genie Pharma has proposed to remove ZHENGYU YUAN (the current chairman and general manager) and three other directors, while nominating three new candidates for the board [2][6]. - The company has been without a controlling shareholder or actual controller since its listing in August 2022, with Genie Pharma and Amgen Hong Kong being the two largest shareholders [2][17]. Group 2: Financial Performance - Amgen Pharmaceuticals has faced significant financial challenges, with net cash flow from operating activities showing negative figures from 2022 to mid-2025, totaling -2.4 billion, -3.29 billion, -4.47 billion, and -1.21 billion respectively [6]. - The company's revenue has increased over the years, but net profit losses have also expanded, with cumulative losses exceeding 1.3 billion from 2021 to 2024 [6]. - As of June 2025, the company's asset-liability ratio reached approximately 60%, and its net assets have decreased by 74.19% since its listing [9]. Group 3: Governance Issues - Genie Pharma criticized ZHENGYU YUAN for failing to fulfill his responsibilities, leading to long-term losses and the risk of delisting [6][9]. - The company has experienced significant delays in the progress of its IPO fundraising projects, which has adversely affected its operations [10]. - There are concerns regarding the strategic investment choices made by the company, particularly in relation to its collaboration with Haiqing Pharmaceuticals, which has faced regulatory penalties [12][14].

Core Insights - Chengdu High-tech Zone is experiencing significant economic growth, with a GDP of 180.91 billion yuan in the first half of 2025, marking a 6.2% increase and accounting for nearly 15% of the city's total GDP [3] - The electronic information industry is a key pillar, with an added value growth rate of 15.9%, and industrial investment exceeding 90% of the total industrial investment in the area [3] Group 1: Government Initiatives - Chengdu has launched a comprehensive service mechanism for enterprises called "进万企、解难题、优环境、促发展," transitioning from "enterprises seeking government" to "government seeking enterprises" [4] - The mechanism has shown effectiveness in various industrial parks, with the government acting as a partner rather than just a landlord [4][5] - The rapid response from the Chengdu High-tech Zone's Digital Economy Bureau has facilitated quick solutions for companies in need of office space and legal assistance [7] Group 2: Industry Development - The Tianfu Changdao Digital Cultural and Creative Park has become a hub for key enterprises in the film production chain, fostering a collaborative environment with a "10-minute cooperation circle" [1][12] - The park has attracted over 60 companies and approximately 6,000 employees, producing over 20 major intellectual properties (IPs) since its opening [15] - Chengdu High-tech Zone is focusing on high-quality development through the "立园满园" initiative, enhancing industrial attraction and ecosystem [12][16] Group 3: Innovation and Achievements - Chengdu High-tech Zone has seen significant achievements in innovation, including the early launch of BOE's 8.6-generation AMOLED production line, which set a new record for construction efficiency [16] - The successful launch of the first domestically produced 4-channel 12-bit 40GSPS high-precision RF direct sampling ADC chip by Chengdu Huamei Electronics Technology Co., Ltd. marks a significant advancement in the high-end RF direct sampling field [19] - The "梧桐计划" provides a comprehensive service system covering the entire lifecycle of enterprises, facilitating project, talent, platform, and financial services [11]

Investment Rating - The report maintains an investment rating of "Outperform the Market" [5] Core Insights - The new drug sector has shown significant movements, with notable increases in stock prices for companies such as Kintor Pharmaceutical, which recently went public in Hong Kong, focusing on unmet clinical needs in oncology and immunology [2][3][21] - The KRAS G12D inhibitor GFH375 from Kintor Pharmaceutical has demonstrated promising clinical data in treating pancreatic cancer and non-small cell lung cancer (NSCLC), with an overall response rate (ORR) of 52% in pancreatic cancer and 68.8% in NSCLC [21][24] Summary by Sections Weekly New Drug Market Review - From September 15 to September 21, 2025, the top five gainers in the new drug sector included Kintor Pharmaceutical (+19.64%), Boan Biotechnology (+8.89%), and others, while the top five losers included Sanofi Pharmaceuticals (-17.16%) and others [1][13] Recommended Stocks to Watch - The report suggests focusing on several potential catalysts in the sector, including academic conferences and insurance negotiations. Key companies to watch include: 1. Differentiated GLP-1 assets: Zai Lab, EQRx, and others 2. Upgraded PD-1 products: CanSino Biologics and others 3. Companies likely to benefit from insurance negotiations: Hengrui Medicine, Kanghong Pharmaceutical, and others [2][17] New Drug Approval and Acceptance - This week, eight new drug applications were approved, and twelve new drug applications were accepted in China [3][25] Clinical Application Approvals - A total of 48 new drug clinical applications were approved, with 32 applications accepted this week [7][29]

Group 1 - Needham maintains a "Buy" rating for Recursion Pharmaceuticals, with a target price of $8, indicating a potential upside of 68% from the current price of $4.77 [1] - Recursion Pharmaceuticals is recognized as one of the top 12 penny stocks favored by Wall Street hedge funds, highlighting its strong market position [1] - The company is leveraging AI technology in drug development, positioning itself as a leader in the field with proprietary datasets [1][2] Group 2 - Gil Blum, a senior analyst at Needham, emphasizes that Recursion has taken significant steps to extend its financial runway, focusing on its flagship product pipeline, which is expected to sustain cash flow until Q4 2027 [2] - The optimistic outlook for Recursion is supported by anticipated clinical results in the next 12 to 18 months, particularly for the solid tumor drug REC-617 [2] - Other Wall Street firms, such as Morgan Stanley and Bank of America, have a more cautious stance, maintaining "Hold" ratings with target prices of $4.8 and $8, respectively [3] Group 3 - Recursion Pharmaceuticals is a clinical-stage biotech company utilizing cutting-edge AI technology to decode biology and chemistry for accelerated drug development [4] - The company's Recursion Operating System (Recursion OS) integrates high-throughput biological experiments, imaging, and machine learning into a unified platform for drug discovery [4][5] - Recent advancements include the BioHive-2 AI supercomputing cluster and acquisitions that enhance its capabilities in biological and chemical modeling [5] Group 4 - The integration of AI in healthcare is projected to grow significantly, with the market value expected to reach $189.9 billion by 2030, reflecting a CAGR of 43.7% [7] - AI is anticipated to optimize various medical processes, including drug discovery, medical imaging, and precision medicine, thereby reducing innovation cycles and improving patient outcomes [7] - The convergence of AI and pharmaceuticals is seen as a revolutionary trend, with potential breakthroughs in drug design and clinical trials expected in the near future [6]